Curbing Adverse Effects of CYP2D6 Substrates

被引：0
|
作者：
不详
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 112卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：933 / 933
页数：1
相关论文
共 50 条
  • [1] In search of endogenous CYP2D6 substrates
    Eichelbaum, M
    PHARMACOGENETICS, 2003, 13 (06): : 305 - 306
  • [2] CYP2D6 genotype and psychotropic drug-induced adverse effects
    Bozina, N
    Tramisak, I
    Medved, V
    Mihaljevic-Peles, A
    Granic, P
    Stavljenic-Rukavina, A
    PERIODICUM BIOLOGORUM, 2001, 103 (04) : 309 - 314
  • [3] Effect of CYP2D6 phenotype and metoprolol pharmacokinetics on adverse effects.
    Beitelshees, AL
    Zineh, I
    Gaedigk, A
    Leeder, JS
    Walker, JR
    Eberst, K
    Timmerbeil, BS
    Lobmeyer, M
    Pauly, DF
    Johnson, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P94 - P94
  • [4] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [5] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
  • [6] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [7] Concurrent use of celecoxib and CYP2D6 substrates common
    Reactions Weekly, 2005, 1067 (1) : 5 - 5
  • [8] CYP2D6 genotype and adverse drug reaction in the ICU
    Stamer, UM
    Bayerer, B
    Hoeft, A
    Stüber, F
    INTENSIVE CARE MEDICINE, 2003, 29 : S13 - S13
  • [9] Effects of CYP2D6 genotypes on pharmacokinetics and adverse reactions of risperidone in healthy volunteers
    Novalbos, J.
    Gallego-Sandin, S.
    Ladona, M. G.
    Higuero, A.
    Diez-Martin, L.
    Pelegrina, M. L.
    Garcia, A. G.
    Abad-Santos, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 103 - 103
  • [10] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
12345